Merck Scores EU CHMP Backing for KEYTRUDA + Padcev in Bladder Cancer Amid Solid Animal Health Momentum

Merck & Co. (NYSE: MRK) recently secured a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for its combination of KEYTRUDA (pembrolizumab) plus Padcev (enfortumab vedotin‑ejfv) as a perioperative treatment for adults with resectable muscle‑invasive bladder cancer (MIBC). The CHMP’s favourable recommendation, issued on September 18, 2026, marks a potential step toward wider EU approval if confirmed by the European Commission.

This development adds to Merck’s strong performance in its Animal Health division, where Q2 2026 sales increased 5% to $1.8 billion, supported by growing livestock and companion-animal demand. Livestock sales rose 6% and companion-animal sales grew 5%, indicating balanced strength across the segment.

Regulatory Advance in Oncology

The CHMP’s positive opinion covers the use of KEYTRUDA plus Padcev as a perioperative therapy in MIBC patients, a move that, if adopted by the European Commission, would enable broader access across EU member states. The approval process remains ongoing following the CHMP recommendation issued on September 18, 2026.

This development underscores Merck’s leadership in immuno-oncology and expands its KEYTRUDA-based portfolio. Market watchers will now watch for the European Commission’s final decision.

Animal Health: A Consistent Growth Engine

On August 4, 2026, Merck reported second-quarter results showing solid performance in both oncology and animal health. The Animal Health segment achieved $1.8 billion in sales, up 5% from the prior year, driven by broad-based growth in livestock (up 6%) and companion animals (up 5%).

This segment continues to benefit from strategic product launches and sustained demand, contributing a stable growth element to Merck’s diversified business.

Why This Matters for MRK Investors

The combination of regulatory momentum in oncology and steady growth in Animal Health underscores Merck’s multi-faceted strength. If the European Commission approves KEYTRUDA plus Padcev for perioperative use in bladder cancer, it could accelerate adoption across Europe and potentially boost oncology revenue.

Meanwhile, the consistent performance of the Animal Health unit reinforces Merck’s resilience amid evolving market conditions. Together, these developments suggest a well-balanced foundation underpinning MRK’s longer-term growth strategy.

What to Monitor Next

• Final European Commission approval of KEYTRUDA plus Padcev for MIBC and expected timing of market launch.
• Future quarterly performance of the Animal Health segment, particularly contributions from new product introductions.
• Any commentary from Merck’s upcoming investor events or Q3 earnings about the European oncology and Animal Health outlook.